美国 · SEC FORM 4
Karyopharm Therapeutics Inc.
KPTI · Nasdaq · CIK 0001503802 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
22 同一窗口内观察到的 Form 4 交易行
10 sales · 12 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 6 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-09-12 · BOHLIN GAREN G.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 6,056,162
- 上期报告
- 7,865,168
- 日均成交量
- 1,263,778
- 回补天数
- 4.8
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-09-12 | BOHLIN GAREN G | 买入 (P) | Common Stock | 41,140 | USD 1.22 | USD 50,191 | SEC 申报 ↗ |
| 2021-05-07 | Shah Jatin | 买入 (P) | Common Stock | 23,250 | USD 8.60 | USD 199,950 | SEC 申报 ↗ |
| 2021-05-06 | BOHLIN GAREN G | 买入 (P) | Common Stock | 4,000 | USD 7.82 | USD 31,280 | SEC 申报 ↗ |
| 2020-08-26 | DEMAREE JOHN | 买入 (P) | Common Stock | 7,500 | USD 14.54 | USD 109,050 | SEC 申报 ↗ |
Form 4 申报证据
39 transaction lines in the latest 365-day window; 410 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Abate Kristin | 卖出 (S) | Common Stock | 378 | USD 1.19 | USD 450 | SEC 申报 ↗ |
| 2026-09-01 | Abate Kristin | 卖出 (S) | Common Stock | 19 | USD 2.02 | USD 38 | SEC 申报 ↗ |
| 2026-07-28 | Poulton Stuart | 卖出 (S) | Common Stock | 189 | USD 7.10 | USD 1,342 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Abate Kristin | 卖出 (S) | Common Stock | 378 | USD 1.19 | USD 450 | SEC 申报 ↗ |
| 2026-09-01 | Abate Kristin | 卖出 (S) | Common Stock | 19 | USD 2.02 | USD 38 | SEC 申报 ↗ |
| 2026-07-28 | Poulton Stuart | 卖出 (S) | Common Stock | 189 | USD 7.10 | USD 1,342 | SEC 申报 ↗ |
| 2026-05-21 | Su Zhen | 奖励／授予 (A) | Common Stock | 15,508 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-21 | Schor Chen | 奖励／授予 (A) | Common Stock | 15,508 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-21 | PAKIANATHAN DEEPIKA | 奖励／授予 (A) | Common Stock | 15,508 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-21 | Oliger Christy J. | 奖励／授予 (A) | Common Stock | 15,508 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-21 | Greene Barry E | 奖励／授予 (A) | Common Stock | 15,508 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-21 | BOHLIN GAREN G | 奖励／授予 (A) | Common Stock | 15,508 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-14 | Rangwala Reshma | 卖出 (S) | Common Stock | 408 | USD 9.50 | USD 3,876 | SEC 申报 ↗ |
| 2026-05-14 | Poulton Stuart | 卖出 (S) | Common Stock | 403 | USD 9.50 | USD 3,828 | SEC 申报 ↗ |
| 2026-05-14 | Paulson Richard A. | 卖出 (S) | Common Stock | 2,203 | USD 9.50 | USD 20,928 | SEC 申报 ↗ |
| 2026-05-14 | Mano Michael | 卖出 (S) | Common Stock | 266 | USD 9.50 | USD 2,527 | SEC 申报 ↗ |
| 2026-05-14 | Cheng Sohanya Roshan | 卖出 (S) | Common Stock | 324 | USD 9.50 | USD 3,078 | SEC 申报 ↗ |
| 2026-05-14 | Abate Kristin | 卖出 (S) | Common Stock | 53 | USD 9.50 | USD 504 | SEC 申报 ↗ |
| 2026-05-13 | Rangwala Reshma | 奖励／授予 (A) | Common Stock | 947 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Poulton Stuart | 奖励／授予 (A) | Common Stock | 896 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Paulson Richard A. | 奖励／授予 (A) | Common Stock | 4,920 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Mano Michael | 奖励／授予 (A) | Common Stock | 700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Cheng Sohanya Roshan | 奖励／授予 (A) | Common Stock | 947 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Abate Kristin | 奖励／授予 (A) | Common Stock | 121 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-21 | Rangwala Reshma | 卖出 (S) | Common Stock | 449 | USD 8.94 | USD 4,014 | SEC 申报 ↗ |
| 2026-03-02 | Rangwala Reshma | 卖出 (S) | Common Stock | 5,066 | USD 9.41 | USD 47,671 | SEC 申报 ↗ |
| 2026-03-02 | Poulton Stuart | 卖出 (S) | Common Stock | 5,101 | USD 9.41 | USD 48,000 | SEC 申报 ↗ |
| 2026-03-02 | Paulson Richard A. | 卖出 (S) | Common Stock | 12,361 | USD 9.41 | USD 116,317 | SEC 申报 ↗ |
| 2026-03-02 | Mano Michael | 卖出 (S) | Common Stock | 3,526 | USD 9.41 | USD 33,180 | SEC 申报 ↗ |
| 2026-03-02 | Cheng Sohanya Roshan | 卖出 (S) | Common Stock | 4,604 | USD 9.41 | USD 43,324 | SEC 申报 ↗ |
| 2026-03-02 | Abate Kristin | 卖出 (S) | Common Stock | 559 | USD 9.41 | USD 5,260 | SEC 申报 ↗ |
| 2026-02-17 | Poulton Stuart | 卖出 (S) | Common Stock | 378 | USD 8.63 | USD 3,262 | SEC 申报 ↗ |
| 2026-02-05 | Paulson Richard A. | 奖励／授予 (A) | Common Stock | 81,060 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | KPTI |
| CIK | 0001503802 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 410 transaction lines from 2020-01-08 to 2026-10-01 4 P purchase lines · 245 S sale lines · 161 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.